Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer
Journal of Clinical Oncology, 07/03/08
Kumar B et al. - In a study to prospectively identify markers of response to therapy and outcome in an organ-sparing trial for advanced oropharyngeal cancer, it was shown that low epidermal growth factor receptor (EGFR) and high p16 (or higher human papillomavirus [HPV] titer) expression are markers of good response to organ-sparing therapy and outcome, whereas high EGFR expression, combined low p53/high Bcl-xL expression, female sex, and smoking are associated with a poor outcome
Methods- Pretreatment biopsies were examined for expression of EGFR, p16, Bcl-xL, and p53 as well as for p53 mutation
- These markers were assessed for association with high-risk HPV, response to therapy, and survival
- Pt variables included smoking history, sex, age, primary site, tumor stage, and nodal status
- EGFR expression was inversely associated with response to induction chemotherapy (IC), chemotherapy/radiotherapy (CRT), overall survival (OS), and disease-specific survival (DSS) and was directly associated with current smoking, female sex, and lower HPV titer
- HPV titer was significantly associated with p16 expression; p16 was significantly associated with response to IC, CRT, OS, and DSS
- As combined markers, lower HPV titer and high EGFR expression were associated with worse OS and DSS
- In 36 of 42 biopsies, p53 was wild-type, and only 1 HPV-positive tumor had mutant p53
- Combination of low p53 and high Bcl-xL expression was associated with poor OS and DSS
Related Articles
Understanding the link between HPV and oropharyngeal cancers
JAAPA, 10/20/09
Relevance Score: 69%%
Current trends in initial management of oropharyngeal cancer: the declining use of open surgery
European Archives of Oto-Rhino-Laryngology, 10/02/09
Relevance Score: 68%%
Oropharyngeal reconstruction using a myomucosal uvular transposition flap following transoral resection of oropharyngeal carcinoma
ENT Journal, 11/20/09
Relevance Score: 66%%
Elevated Malondialdehyde Correlates with the Extent of Primary Tumor and Predicts Poor Prognosis of Oropharyngeal Cancer
Anticancer Research, 11/13/09
Relevance Score: 66%%
Immunostaining patterns of CD31 and podoplanin in previously untreated advanced oral/oropharyngeal cancer: Prognostic implications
Head & Neck, 11/05/09
Relevance Score: 65%%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell–fibronectin adhesion of colon cancer cells
Oncogene, 11/25/09
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
Oncogene, 11/25/09
Embryoid body formation of human amniotic fluid stem cells depends on mTOR
Oncogene, 11/25/09
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Paraneoplastic syndromes in patients with oral cancer
Oral Oncology , 11/25/09
Early radiation-induced laryngeal malignant fibrous histiocytoma (MFH)
Clinical and Translational Oncology, 11/25/09
Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: Result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution
European Journal of Cancer, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


